TABLE 4.
Reports of the body mass index on immune checkpoint inhibitor therapy for pretreated advanced non‐small cell lung cancer
| Report | Year | Region | Study type | Sample size | Stage | Treatment | BMI cutoff | Treatment line | Outcome according to BMI HR (95% CI), p‐value | |
|---|---|---|---|---|---|---|---|---|---|---|
| PFS | OS | |||||||||
| Popinat et al. 27 | 2019 | France | Retrospective | 55 | IV | Nivolumab monotherapy | 24.7 | Pretreated (≥second line) | NR |
(High/Low): NR, p = 0.082 OS tends to be longer |
| Ichihara et al. 22 | 2020 | Japan | Retrospective | 429 | Advanced, recurrence | Pembrolizumab, nivolumab, or atezolizumab monotherapy | 22.0 | Pretreated (≥second line) |
(High/Low): 0.79 (0.64–0.98), p = 0.036 |
(High/Low): 0.73 (0.57–0.95), p = 0.021 |
| Kichenadasse et al. 28 | 2020 | Global | Prospective | 1434 | IV, recurrence | Atezolizumab monotherapy | 25.0 | Untreated and pretreated |
(High/Low): overweight, 0.89 (0.78–1.01), p = 0.09, obese, 0.86 (0.73–1.01), p = 0.09 |
(High/Low): overweight, 0.81 (0.68–0.95), p < 0.001, obese, 0.64 (0.51–0.81), p < 0.001 |
| Dimitrakopoulos 29 | 2020 | Greece | Retrospective and prospective | 112 | III–IV | Pembrolizumab or nivolumab monotherapy | 26.26 | Untreated and pretreated (≥second‐line) |
(High/Low): 0.738 (0.471–1.156), p = 0.160 |
(High/Low): 0.853 (0.507–1.436), p = 0.542 |
| Takada et al. 30 | 2020 | Japan | Retrospective | 226 | IIIB–IV, recurrence | Pembrolizumab or nivolumab monotherapy | 19.1 | Untreated and pretreated (≥second‐ line) |
(Low/High): 1.47 (1.04–2.05), p = 0.0269 |
(Low/High): 1.29 (1.10–2.30), p = 0.0138 |
| Dragomir et al. 31 | 2021 | Romania | Retrospective | 80 | I–IV | Nivolumab monotherapy | 25.0 | Pretreated |
(High/Low): 0.96 (0.96–1.91), p = 0.001 |
NR |
| Current study | Japan | Retrospective | 99 | III–IV, recurrence | Nivolumab monotherapy | 22.1 | Pretreated (second‐line only) |
(Low/High): 1.29 (0.84–1.97), p = 0.22 |
(Low/High): 1.79 (1.10–2.93), p = 0.0184 |
|
Note: p‐values in bold are statistically significant (p < 0.05).
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; NR, not reported; OS, overall survival; PFS, progression‐free survival.